In a nutshell This study looked at the effectiveness of mismatched donor stem cell transplantation (SCT) for treating children with high-risk relapse of acute lymphoblastic leukemia (ALL). Researchers found that mismatched donor SCT was useful but not as effective as matched donor SCT in children with high-risk ALL. Some background Acute lymphoblastic...
Read More
In a nutshell This study investigated the safety and effectiveness of alloHCT (allogeneic hematopoietic stem cell transplantation) in patients with chronic lymphocytic leukemia (CLL) pre-treated with ibrutinib (Imbruvica). This study concluded that ibrutinib does not affect the safety of alloHCT. Some background Ibrutinib has become the standard of...
Read More
In a nutshell This study examined the effectiveness of thiotepa-based RIC in leukemia and lymphoma patients undergoing stem cell transplantation. The authors concluded that this treatment improved outcomes compared to standard RIC. Some background Before undergoing stem cell transplantation, patients with lymphoma or leukemia must undergo conditioning...
Read More
In a nutshell This study aimed to investigate if dasatinib could be successfully discontinued in chronic myeloid leukemia patients who were receiving it as a second line treatment after a year of deep molecular response. This study concluded that it was possible to discontinue dasatinib use in this group of patients. Some background Imatinib...
Read More
In a nutshell This study aimed to evaluate the effect of sorafenib (Nexavar) on the outcomes of patients with acute myeloid leukemia (AML) with FMS-like tyrosine kinase 3 (FLT3)–internal tandem duplication (ITD) undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT). This study concluded that sorafenib before or after...
Read More
In a nutshell This study aimed to investigate the effectiveness and safety of ponatinib (Iclusig) for patients with chronic phase chronic myelogenous leukemia. This study concluded that ponatinib is safe and effective in this group of patients. Some background The Philadelphia chromosome (BCR-ABL1) is found in almost all patients with chronic...
Read MoreIn a nutshell This study aimed to investigate the safety and effectiveness of ibrutinib (Imbruvica) in chronic lymphocytic leukemia. This study concluded that long-term administration of ibrutinib was well tolerated and provided effective disease control for most patients. Some background Ibrutinib is a targeted therapy that can be used for...
Read More
In a nutshell This study aimed to investigate the safety and effectiveness of nilotinib (Tasigna) in patients with chronic phase chronic myeloid leukemia who have an intolerance to other tyrosine kinase inhibitors. This study concluded that this group of patients can be treated with nilotinib and it can lead to deep molecular responses. Some background...
Read More
In a nutshell This study aimed to investigate risk factors that influence the outcome of acute leukemia patients who experience relapse after hematopoietic stem cell transplant. This study concluded that certain factors, such as older age and not acheiving remission after relapse treatment, are associated with worse survival outcomes. Some...
Read More
In a nutshell This study examined the long-term safety and effectiveness of bendamustine (Treanda) in lymphoma and leukemia. This study concluded that bendamustine is a safe and effective therapy for these patients. Some background Bendamustine has been shown to have high effectiveness and few side effects for a wide range of lymphomas. This drug is...
Read More
In a nutshell This study examined causes and outcomes of a chromosomal abnormality known as 17p deletion in chronic lymphocytic leukemia (CLL). Researchers reported poor outcomes for patients that have both 17p deletion and 8q24 gain. Some background Certain genetic changes in CLL can make it more difficult to treat. Changes in the chromosomes, such...
Read More
In a nutshell This study examined treatment responses to imatinib (Glivec) in chronic myeloid leukemia (CML) patients. Researchers reported that about half of patients achieved an optimal response to treatment that could allow patients to safely stop therapy. Some background Molecular response (MR) is a response to treatment where hardly any or no...
Read More
